Advertisement
Research Article

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1

  • Frank van Leth,

    Affiliation: International Antiviral Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands

    X
  • Prahpan Phanuphak,

    Affiliation: Thai Red Cross AIDS Research Center, Bangkok, Thailand

    X
  • Erik Stroes,

    Affiliation: Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands

    X
  • Brian Gazzard,

    Affiliation: Chelsea and Westminster Hospital, London, United Kingdom

    X
  • Pedro Cahn,

    Affiliation: Fundacion Huesped, Buenos Aires, Argentina

    X
  • François Raffi,

    Affiliation: University Hospital, Nantes, France

    X
  • Robin Wood,

    Affiliations: Sommerset Hospital, Capetown, South Africa, University of Capetown, South Africa

    X
  • Mark Bloch,

    Affiliation: Holdsworth House General Practice, Darlinghurst, Australia

    X
  • Christine Katlama,

    Affiliation: Hospital Pitie-Salpetriere, Paris, France

    X
  • John J. P Kastelein,

    Affiliation: Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands

    X
  • Mauro Schechter,

    Affiliations: Hospital Sao Francisco de Assis, Rio de Janeiro, Brazil, Hospital University Clementino Fraga Filoho, Rio de Janeiro, Brazil

    X
  • Robert L Murphy,

    Affiliation: Northwestern University, Chicago, Illinois, United States of America

    X
  • Andrzej Horban,

    Affiliation: Wojewodzki Szpital Zakazny, Warsawa, Poland

    X
  • David B Hall,

    Affiliation: Boehringer Ingelheim, Ridgefield, Connecticut, United States of America

    X
  • Joep M. A Lange,

    Affiliation: International Antiviral Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands

    X
  • Peter Reiss

    Affiliation: International Antiviral Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands

    X
  • Published: October 19, 2004
  • DOI: 10.1371/journal.pmed.0010019

About the Authors

Frank van Leth, Joep M. A Lange, Peter Reiss
International Antiviral Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
Prahpan Phanuphak
Thai Red Cross AIDS Research Center, Bangkok, Thailand
Erik Stroes, John J. P Kastelein
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
Brian Gazzard
Chelsea and Westminster Hospital, London, United Kingdom
Pedro Cahn
Fundacion Huesped, Buenos Aires, Argentina
François Raffi
University Hospital, Nantes, France
Robin Wood
Sommerset Hospital, Capetown, South Africa
Robin Wood
University of Capetown, South Africa
Mark Bloch
Holdsworth House General Practice, Darlinghurst, Australia
Christine Katlama
Hospital Pitie-Salpetriere, Paris, France
Mauro Schechter
Hospital Sao Francisco de Assis, Rio de Janeiro, Brazil
Mauro Schechter
Hospital University Clementino Fraga Filoho, Rio de Janeiro, Brazil
Robert L Murphy
Northwestern University, Chicago, Illinois, United States of America
Andrzej Horban
Wojewodzki Szpital Zakazny, Warsawa, Poland
David B Hall
Boehringer Ingelheim, Ridgefield, Connecticut, United States of America

Corresponding Author

Email: f.vanleth@iatec.com

Competing Interests

FvL has received travel grants and honoraria for presentations from Boehringer Ingelheim and travel grants from GlaxoSmithKline. PP has received research grants and honoraria for speaking from GlaxoSmithKline, Bristol-Myers Squibb, Roche, Merck Sharp and Dohme, and Boerhinger Ingleheim. BG has received grants and honoraria from Abbott Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Gilead, and Boehringer Ingleheim. FR has received research grants and honoraria from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Abbott, and Boehringer Ingleheim. RW is conducting clinical research supported by GlaxoSmithKline, Boehringer Ingelheim, Pfizer, and Bristol-Myers Squibb. MB is currently conducting clinical studies supported by Boehringer Ingelheim, Bristol-Myers Squibb, and Merck. CK has received grants and honoraria for speaking from Bristol-Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim, Bayer, and Roche. MS has received research grants, travel grants, and honoraria for speaking from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Gilead, Merck, and Roche. RLM has received honoraria for consultancies from Boehringer Ingelheim and Bristol-Myers Squibb. AH has received honoraria for presentations from Boehringer Ingleheim. DBH is employed by Boehringer Ingelheim, the manufacturer of one of the trial medications. JMAL has received honoraria as an advisor for GlaxoSmithKline, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Merck Sharp and Dohme, Schering-Plough, Bayer, Shire Pharmaceuticals, Agouron/Pfizer, and Virco/Tibotec. PR, in the last five years, has received honoraria for speaking engagements from Boehringer Ingelheim. JMAL is a member of the editorial board of PLoS Medicine.

Author Contributions

FvL, ES, DBH, JMAL, and PR designed the study. FvL and DBH analysed the data. PP, BG, PC, FR, RW, MB, CK, MS, RLM, and AH enrolled patients. FvL wrote the first draft of the paper. All authors contributed to the writing of the final version of the manuscript.